Research and development
Innovation is the driving force behind Crucell’s future growth supported by a strong research and development (R&D) pipeline. Our scientists focus on the discovery and development of much-needed solutions for major threats to human health—particularly vaccines and antibodies for the prevention and treatment of infectious diseases. This has resulted in a broad pipeline of investigational products with the potential to revolutionize the fight against diseases such as influenza, rabies, malaria and tuberculosis.
In this section you can read more about the discovery and development of next-generation medical products facilitated by our range of innovative technologies.
From discovery to market
Our current R&D pipeline includes the following product areas:
Vaccines:
- Classical vaccines: Many viruses have been shown to grow extremely well on Crucell's PER.C6® cells under controlled and scalable conditions. These viruses can then be inactivated, purified and marketed as inactivated whole virus (also called 'whole-killed'), split or subunit vaccines.
- Recombinant vaccines: Our adenovirus-based AdVac® vectors can be used to create recombinant (engineered) vaccines by inserting a small piece of genetic material from the disease causing virus into a harmless adenoviral vector that acts as a 'vehicle'. The recombinant vaccine triggers an immune response against this specific virus in vaccinated individuals, so that they are protected from a later attach by the disease-causing virus. The AdVac®-based vaccine can be manufactured to large-scale commercial volumes on the PER.C6® human cell line.
Antibodies:
-
Recombinant antibodies: Recombinant antibodies, such as blood factors, can be produced efficiently and safely on the PER.C6® human cell line.
- Antibodies: MAbstract® technology is used to identify strong binding and neutralizing antibodies for specific disease targets. Antibodies discovered in this way can then be produced using PER.C6® technology.
Learn more about Crucell’s development programs
E-MAIL THIS PAGE
PRINT THIS PAGE